Pharma News

Frontier Medicines Announces Series C Funding to Advance Development of Next Generation KRAS Blocker

Photo of MEEFRO MEEFRO Send an email February 23, 2024
0 124,533 Less than a minute

Funds expected to advance multiple programs into clinical studies, including FMC-376, which targets KRASG12C cancers.

Source link
#Frontier #Medicines #Announces #Series #Funding #Advance #Development #Generation #KRAS #Blocker

Photo of MEEFRO MEEFRO Send an email February 23, 2024
0 124,533 Less than a minute
Photo of MEEFRO

MEEFRO

Related Articles

What is the current valuation of AstraZeneca’s Sabestomig

April 16, 2024

What is the current valuation of AbbVie’s ABBV-400

April 16, 2024

What is the current valuation of Merck’s MK-1084

April 16, 2024

What is the current valuation of AstraZeneca’s AZD-9574

April 16, 2024

Leave a Reply

Your email address will not be published. Required fields are marked *